shutterstock_274849448 - Clinical Trials Arena
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

Lexicon’s reliance on risk mitigation protocols for type 1 diabetes pursuit for Zynquista elicits mixed reactions

Efforts by Lexicon Pharmaceuticals to have Zynquista approved for type 1 diabetes has split experts on whether protocols to reduce the diabetic ketoacidosis (DKA) risk will be sufficient.